Tumor suppressor-like mutations mark a dosage-constrained dependency in leukemia
Lee, J. D.; Uyemura, M. M.; Lamini, F.; Posey, R. R.; Shin, E. H.; Harris, A. C.; Ottone, T.; Cheloni, G.; Chou, D. B.; Trinh, B. Q.; Paulo, J. A.; Tenen, D. G.; Clohessy, J. G.; Voso, M. T.; Graubert, T. A.; Slack, F. J.
Show abstract
Cancer genes are classically categorized as oncogenes or tumor suppressors based on whether gain or loss of function promotes malignancy. Here we show that oncogene-imposed dosage constraints can produce mutations that mimic tumor suppressor loss yet mark essential genes. In acute promyelocytic leukemia (APL), the transcription factor EBF3 gene harbors recurrent heterozygous loss-of-function mutations, a tumor suppressor signature, and is essential for APL survival. We resolve this paradox by showing that while PML::RARA, the fusion oncoprotein defining APL, drives EBF3 expression, excess EBF3 suppresses proliferation. Patient mutations reduce EBF3 activity through heterozygous inactivation, optimizing its expression within a corridor bounded by fitness constraints at both extremes. PML::RARA activates EBF3 via a p300-dependent intronic enhancer, and p300 inhibition exploits this constraint by suppressing EBF3 below the viability threshold. Our findings reveal that oncogenes can impose dosage constraints that drive adaptive mutations conventionally misclassified as tumor suppressor loss, with implications for interpreting cancer genomes.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression between patients 93%
- Disruption of a GATA2, TAL1, ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells 93%
- ZNF410 uniquely activates the NuRD component CHD4 to silence fetal hemoglobin expression 92%
Similar papers in this journal
- TCF3::HLF Orchestrates an Enhancer-Promoter Network with Activation of MEF2C to Promote Immature HSC gene Expression in Leukemia 93%
- Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers 93%
- 7q11.23 Syndromes Reveal BAZ1B as a Master Regulator of the Modern Human Face and Validate the Self-Domestication Hypothesis 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.